The definition of original acute severe autoimmune hepatitis (AS-AIH) is unclear. However, its rapid recognition and early treatment is potentially life-saving. Therefore, we present herein an open, real-world observational study for the assessment of the efficacy and safety of early high-dose i.v. corticosteroids in original AS-AIH patients.
INTRODUCTION
A UTOIMMUNE HEPATITIS (AIH) is a chronic liver disease characterized by female preponderance, hypergammaglobulinemia, circulating autoantibodies, association with human leucocyte antigen (HLA)-DR3 and -DR4, and interface hepatitis on liver histology. 1, 2 Its clinical presentation ranges from asymptomatic to acute severe AIH (AS-AIH) or even acute liver failure (ALF). [1] [2] [3] The acute form is observed in approximately 20% of patients either as an exacerbation of chronic disease or as a newly diagnosed AIH without findings of chronic disease in liver biopsy (original AS-AIH). [2] [3] [4] [5] [6] There are several problems in diagnosing the acute onset of AIH as in this setting as 25-39% of patients might show normal immunoglobulin G (IgG) and 9-17% are seronegative for autoantibodies. 1, 2, [7] [8] [9] [10] [11] Histology could also be atypical, especially in ALF patients. 3, 4, 7 Moreover, the diagnostic scores for AIH were designed to differentiate AIH from other chronic liver diseases, rather than to address diagnostic considerations of AS-AIH or ALF due to AIH. 1, 2, 5, 6, [12] [13] [14] [15] [16] [17] The proposed definition of AIH-ALF by the US Acute Liver Failure Study Group (ALFSG) encompasses the ALF definition, together with the presence of certain clinical and histological criteria, in an attempt to differentiate AIH-ALF from other ALF etiologies. 3 However, the designation of original AS-AIH has not yet been codified by international panels, resulting in use of arbitrary definitions by different groups. 9, [18] [19] [20] [21] [22] Therefore, guidelines for original AS-AIH management are missing, and the usefulness of corticosteroids as well as their dosage and route of administration remain controversial. [23] [24] [25] Our aim was to delineate the characteristics and outcomes of patients presenting with original AS-AIH and to investigate the role of high-dose i.v. corticosteroids during the early phase of the disease, before full-blown ALF is developed.
METHODS

I
N THE ABSENCE of a standardized definition, original AS-AIH was defined as an acute symptomatic presentation of well-established newly diagnosed acute hepatitis without any sign of hepatic encephalopathy (time between the onset of symptoms and acute hepatitis presentation <24 weeks and transaminases >10× upper limit of normal [ULN] ) with international normalized ratio (INR) ≥1.5 and bilirubin ≥4 mg/dL at any time during the acute course of AIH without histological lesions of chronic disease.
Forty-two patients identified with an acute severe presentation from our entire prospective database of 184 AIH patients (Fig. 1) . However, in order to include only true AS-AIH patients, prospectively collected data from 34 patients who fulfilled the above criteria for original AS-AIH were finally retrospectively analyzed; the remaining eight patients with AS-AIH had histological lesions of chronic disease (acute on chronic AS-AIH; three with severe fibrosis and five with cirrhosis). The control group consisted of 117 patients with insidious presentation (not-AS-AIH) (Fig. 1) . The baseline characteristics of patients included in the final analysis (n = 151) are shown in Table 1 . All patients diagnosed and followed in our department (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) fulfilled the AIH criteria established by the International AIH Group (IAIHG). 12, 13 Genetic, viral, toxic, and metabolic causes were appropriately ruled out.
The Model for End-stage Liver Disease (MELD) score was also calculated, as it correlates with response to treatment. 25, 26 All subjects gave written informed consent to participate in the study at the time of interview. The ethical committee of Larissa University Hospital (Larissa, Greece) approved the protocol that conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution's human research committee.
Autoantibody testing
Antinuclear antibodies (ANA), smooth muscle antibodies (SMA), antibodies against liver kidney microsomal type-1 (anti-LKM1), and against liver cytosol type-1 (anti-LC1) were initially detected by indirect immunofluorescence on 5-μm fresh frozen sections of in-house rodent kidney, liver, and stomach tissue substrates as we described previously. 1, 11, [27] [28] [29] [30] Anti-LKM1, anti-LC1, and antibodies against soluble liver antigen/liver pancreas (anti-SLA/LP) were also evaluated by immunoblotting using rat liver microsomal or cytosolic extracts. 1, 11, 29 Commercially available enzyme-linked immunosorbent assay kits using recombinant SLA/LP/tRNP (Ser) Sec (Inova Diagnostics, San Diego, CA, USA) and formiminotransferase cyclodeaminase (Euroimmun Medizinische Labordiagnostika, Lubeck, Germany) were also used for anti-SLA/ LP and anti-LC1 determination respectively, according to the manufacturer's instructions. 
Determination of HLA
At the time of interview, 94/151 patients (62%; 95% confidence interval [CI]: 54-70%) consented for determination of the HLA pattern by polymerase chain reaction sequence-specific oligonucleotides (Table 1) .
Liver histology
All biopsies were assessed using the Knodell histologic/activity index score. 31 According to previous publications of our group, [27] [28] [29] [30] patients were divided into two groups according to inflammation (minimal-mild [score, 0-8] and moderate-severe [score, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] ) and fibrosis (minimal/mild-moderate [score, 0-2] and severe fibrosis-cirrhosis [score, [3] [4] . Detailed description of biopsies from original AS-AIH patients was included in the analysis.
Treatment
In this open, real-world observational study all 34 original AS-AIH patients treated initially with high-dose i.v. corticosteroids either with 1 g methylprednisolone/day for 3 consecutive days followed by i.v. 1 mg/kg/day prednisolone (n = 7/34; 20.6%) or with high-dose (1.5 mg/kg/ day) i.v. prednisolone from the beginning of treatment, immediately after the exclusion of all other causes of acute hepatitis (3-10 days after the onset of symptoms). Younger patients and/or those without concurrent metabolic disorders like poorly controlled hypertension, obesity, and diabetes were treated with pulsed steroids (the rest with 1.5 mg/kg/day i.v. prednisolone). The switch to oral prednisolone (1 mg/kg/day) was done when INR was ≤1.3, bilirubin ≤3 mg/dL, and the patient was clinically improved (after 7-14 hospital days). In the not-AS-AIH group, 88/117 were eligible for treatment (75.2%; 95% CI, 66-82.5), as 29 patients had already established burn-out decompensated or compensated cirrhosis with minimal or no necroinflammatory activity. These 88 patients were treated according to European Association for the Study of the Liver (EASL) guidelines with prednisolone 0.5-1 mg/kg/day at one daily dose orally in the morning. 2 In all patients (original AS-AIH and not-AS-AIH) who were eligible for treatment, the gradual tapering schedule of oral prednisolone was done according to our previous reports.
27 -29 In more detail, the tapering dose of prednisolone was 5 mg/week until the dose reached 15 mg, followed by a tapering rate of 2.5 mg/week according to the biochemical and clinical response, until complete withdrawal. [27] [28] [29] In addition, all treated patients apart from prednisolone were also received in combination with either mycophenolate mofetil (MMF) according to the protocol published by our group or azathioprine (AZA) at a dose of 1-2 mg/kg/day. [27] [28] [29] In brief, MMF was started at a dose of 1 g/day and then gradually increased after 3 weeks to a final dose of 1.5-2 g/day which was maintained for at least 2 years after complete response (CR). This fixed final dose was decided according to its proven efficacy in suppressing the immune response in our previous reports, [27] [28] [29] as well as in reports on other autoimmune diseases and also in AIH patients intolerant and/or non-responsive to standard therapy. [32] [33] [34] After corticosteroid withdrawal and when normalization of biochemical parameters (transaminases and IgG) had been achieved for at least 6 months, in addition to the absence of any sign of clinical exacerbation, the MMF dose was gradually reduced to 1-1.5 g daily in an attempt to achieve maintenance of immunosuppression at a minimal effective dose while minimizing the likelihood of its long-term side-effects. Mycophenolate mofetil or AZA were started if bilirubin was ≤4 mg/dL.
Treatment end-points were defined according to EASL guidelines and our previous reports as CR, partial response (PR), no response (NR), and relapse (RE). 2, 27, 28 In brief, CR was defined by transaminases and IgG normalization, improvement or disappearance of symptoms, and liver histology, if carried out, showing minimal or no inflammation. Partial response was defined by partial decrease of transaminases below 2× ULN without achieving complete normalization and inability to withdraw or taper prednisolone. No response was defined by persistently elevated transaminases above 2-3× ULN and/or high IgG despite intensive immunosuppression and reassurance of adherence to therapy. Relapse was defined by transaminase rise >2-3× ULN and/or IgG >2000 mg/dL with or without reappearance of symptoms at any time-point during therapy following an initial CR. Treatment was withdrawn when immunosuppression had been given for at least 4 years and only if patients had achieved CR at least for the last 2 years of treatment. Liver biopsy was recommended to all patients fulfilling the withdrawal criteria.
Statistical analysis
Results are expressed as median (range) and mean ± stanndard deviation where appropriate. (Fig. 1) .
According to the IAIHG criteria, 23 (67.6%; 95% CI, 49-82) patients with original AS-AIH had definite AIH, while 11 (32%; 95% CI, 18-50) had probable AIH. 12, 13 In more detail, according to the simplified and revised IAIHG scores, 20/34 (58.8%; 95% CI, 41-75) and 16/34 (47%; 95% CI, 30-64) patients had definite AIH, respectively. The median MELD score was 18 (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) .
All original AS-AIH patients tested positive for either ANA or SMA (titers ≥1/80; range, 1/80-1/1280). Only three AS-AIH patients (8.8%; 95% CI, 2-25) had normal IgG; the rest had IgG >1.1× ULN and 18/34 (52.9%; 95% CI, 35-70) had IgG >1.5× ULN.
Histological findings
Histology was available in 30/34 (88.2%) original AS-AIH patients. In the remaining patients, liver biopsy either could not be carried out because of significant coagulation impairment on admission or because patients refused the procedure. However, these four patients fulfilled the rest of the criteria for AIH (positive liver autoimmune serology, increased IgG, exclusion of viral and other liver disorders, and a favorable response to immunosuppression), and they had no clinical or radiological signs of chronic liver disease. Interface hepatitis had 21/30 (70%; 95% CI, (Table S1 ).
Outcome and response to treatment of original AS-AIH patients Only 1/34 (2.9%; 95% CI, 0.1-17) died due to sepsis on day 26 after diagnosis, being on the waiting list for liver transplantation (LT) because of ALF development. No other short-or long-term serious adverse event was observed in original AS-AIH patients, although they received high-dose i.v. corticosteroids. No patient underwent LT.
Patients with original AS-AIH were followed for 65 (1-175) months. No other patient died during the follow-up (overall long-term and long-term liver-related survival, 33/34; 97%). At the time of this writing, no patient required LT whereas 2 patients lost to follow-up after 13 and 25 months.
Original AS-AIH patients received treatment for 55.5 (14-298) months. Prednisolone and MMF was given to 28 (82.4%; 95% CI, 65-92.6%), prednisolone and AZA to three (8.8%; 95% CI, 2.3-24.8%), and prednisolone alone three (8.8%; 95% CI, 2.3-24.8%) patients. Overall, 27 patients (79.4%; 95% CI, 61.6-90.6) achieved CR, two (5.9%; 95% CI, 1-21) PR, four (11.8%; 95% CI, 3.8-28) had RE, and one (2.9%; 95% CI, 0.1-17) had NR. The only variable associated with CR was lower MELD score (13.3 ± 2.3 in CR vs. 19.8 ± 3.4 in non-CR; P = 0.05). The kind of treatment (prednisolone + MMF vs. prednisolone + AZA vs. prednisolone alone), the treatment schedule (methylprednisolone pulses followed by i.v. prednisolone vs. high-dose i.v. prednisolone from the beginning of treatment) and the grading and staging of original AS-AIH patients did not affect treatment response, although the sample number is very small for safe conclusions.
In order to exclude patients who received treatment for a short period, which could bias the estimation of treatment response, patients treated for at least 12 months were also analyzed (n = 28) resulting in 23 (82.1%; 95% CI, 62.4-93) CR, one (3.6%; 95% CI, 0.2-20) PR, and four (14.3%; 95% CI, 4.7-33.5) with initial CR followed by RE.
Comparison between original AS-AIH and not-AS-AIH patients
As expected, original AS-AIH patients had significantly higher baseline transaminases, INR, bilirubin, and IgG (P = 0.001 for all comparisons; Table 1 , Fig. 2 ). Original AS-AIH patients were more frequently ANA negative (P = 0.038) and they had higher simplified scores compared to not-AS-AIH patients (P = 0.002).
Seven of 34 original AS-AIH patients received induction therapy with 1 g methylprednisolone. The rest received i.v. prednisolone at a dose of 63.2 ± 13.7 mg/day, which differed significantly from the not-AS-AIH patients (33 ± 11, P = 0.001). Considering not-AS-AIH patients, 75 (85%; 95% CI, 75.7-91.6% received prednisolone and MMF, nine (10.2%; 95% CI, 5-19%) prednisolone and AZA, and four (4.5%; 95% CI, 1.4-11.8%) only prednisolone (no statistically significant difference compared to original AS-AIH). The MMF and AZA durations did not differ between original AS-AIH and not-AS-AIH patients (MMF, 62 ± 44 vs. 56.5 ± 37 months; AZA, 36 ± 24.5 vs. 50 ± 38 months).
When only patients treated for >12 months were taken into account, original AS-AIH patients (n = 28) had significantly more frequent CR compared to not-AS-AIH patients (n = 79; P = 0.026; Fig. 3 ). Corticosteroids withdrawal was also significantly more frequent in original AS-AIH patients (P = 0.016; Fig. 4) , even though the duration of corticosteroids did not differ between the groups (10 [5-37] months, n = 26 vs. 11.5 months, n = 53; P > 0.05).
In univariate analysis, treatment response (CR vs. PR + RE + NR) was associated with presence of original AS-AIH (P = 0.013) and absence of cirrhosis at diagnosis (P = 0.016). After multivariate binary logistic regression analysis, only original AS-AIH presence independently predicted CR (Table S2 ). The frequency of RE after treatment discontinuation did not differ between original AS-AIH (n = 13, 2 RE and 11 in remission for 28.5 ± 20 months) and not-AS-AIH patients (n = 28, 7 RE and 21 in remission for 27.3 ± 22 months).
DISCUSSION
W E DEFINED ORIGINAL AS-AIH as an acute symptomatic presentation of well-established newly diagnosed acute hepatitis (by definition elevated transaminases of at least 10× ULN) without histological lesions of chronic disease with INR ≥1.5 and bilirubin ≥4 mg/dL, at any time during the acute course of the disease, using a similar INR threshold as that used for the definition of ALF by US-ALFSG. 3 We excluded from the final analysis patients with acute severe presentation who had severe fibrosis and/or cirrhosis on liver biopsy (not real original but acute on chronic AIH cases) as well as patients from the control group who had an acute presentation but without achieving the definition of AS-AIH, in order to accomplish homogeneity in the two comparison groups (Fig. 1) . However, we gave special attention to the safety and assessment of treatment response and outcome of original AS-AIH patients after i.v. treatment with high-dose corticosteroids.
The main findings that arose from our real-world study were: (i) as published recently in a large nationwide Japanese survey, 35 patients with original AS-AIH had significantly higher aminotransferases, IgG, INR, and bilirubin, confirming that this group had a more severe disease phenotype; (ii) the simplified score can help to achieve a timely and prompt AIH diagnosis in patients who present with the original AS form; and, most importantly, (iii) presence of original AS-AIH was the only independent predictor for achieving CR after prompt initiation of high-dose i.v. corticosteroids (approximately 7-10 days from symptoms) which proved safe and efficient. This treatment seems to prevent disease deterioration. In addition, the long-term treatment response and corticosteroids withdrawal rates were significantly better in these patients than in not-AS-AIH cases.
Similar good treatment response and long-term prognosis have been recently reported in a retrospective analysis of 30 Japanese patients with an acute but not severe form of the disease. 36 Absence of ANA reactivity almost in half of our AS-AIH patients is not a surprise as previous studies have shown that ANA and/or SMA could be negative in patients with acute AIH, a finding that might lead to delay of diagnosis. 1, [9] [10] [11] 37 Contrary to previous reports but in agreement with others, the majority of our patients had IgG >1.1× ULN. 4, 5, 16, 17, 27 The positive liver autoimmune serology and increased IgG justify that the simplified AIH score was at least 6 (probable AIH) in all original AS-AIH patients. The revised IAIHG score performed equally well. Yeoman et al. showed that the revised score was more sensitive for AIH diagnosis (40% vs. 24%), even though the simplified criteria were more specific.
14 Considering liver histology, more than 70% of our patients with original AS-AIH had interface hepatitis and/or lobular necrosis/inflammation; not surprisingly, 40% had centrilobular necroinflammation, which has been proposed as the hallmark of AIH-ALF by US-ALFSG. 3 These findings on histology are in parallel with a big nationwide study from Japan including 1682 AIH patients (35.4% of patients presenting centrilobular necrosis). 35 In another recent retrospective histological evaluation of 87 Japanese patients with acute AIH, it was shown that, in accordance with the US-ALFSG findings, 3 the patients had prominent lobular and perivenular necroinflammation (including centrilobular necrosis), pigmented macrophages, and cobblestone appearance of hepatocytes along with typical AIH features, like plasma cell infiltration and emperipolesis. 38 All 34 AS-AIH patients were promptly treated within 7-10 days after the onset of symptoms. Of note, the patients had a median INR of 1.52, which shows that they were not "too sick" and that treatment was initiated promptly enough in order to interrupt the catastrophic process and prevent deterioration of liver function and ALF development.
To the best of our knowledge, this is the first study evaluating response of original AS-AIH to high-dose i.v. corticosteroids. These doses were used according to the rational of treatment for other "catastrophic" diseases with increased mortality, such as vasculitis or secondary hemophagocytic syndrome. 39, 40 Indeed, i.v. methylprednisolone pulse therapy has been used in other conditions like rheumatological diseases, in comparison to conventional prednisolone, in an attempt to reduce corticosteroid-associated side-effects and achieve a rapid remission of disease activity, which is of course crucial for AS-AIH cases. This strategy proved safe and effective in a small study in children with AIH, 41 as was the case in our cohort as, apart from one patient who progressed to ALF with hepatic encephalopathy and sepsis and eventually died, no other serious adverse events were observed either in the short or long term.
The role of corticosteroids in modifying the original AS-AIH outcome remains unclear, as it is ambiguous whether such patients should be given a trial of corticosteroids, placed on a priority list for LT, or both. 2 Furthermore, the dosing schedule, route of administration, at what time point during the disease process treatment should be initiated. Potts and Verma reviewed five retrospective studies, each with a small patient number, including 85 patients with AIH-ALF. 42 Sixty-nine patients (89.2%) received immunosuppression therapy, mostly oral corticosteroids, with remission rates of 8.3%-50%; 43.5% of patients underwent or were listed for LT, and 33% died. Another preliminary retrospective multicenter French study in AS-AIH reported overall survival of 90% (median follow-up, 2.3 years) although early LT was required in one-third of patients and the beneficial effect of corticosteroids in 66% of patients was mainly observed in those with low INR at baseline and improvement of liver function during the first week of treatment. 43 The conflicting results were attributed to the heterogeneity of the cohorts included in these studies, as attested by the MELD score. A MELD score >28 carried a dismal prognosis. Our study is more comparable to those of Yeoman et al. and Moenne-Loccoz et al., who assessed the efficacy of corticosteroids in AS-AIH patients, using definition criteria approximately similar to our study. 9, 18 The first study included 23 patients, most of whom received 20-40 mg prednisolone orally within 4 weeks of jaundice onset. Half of the patients responded and the rest received LT or died. The second study included 15 patients who received 40-100 mg corticosteroids within a median of 25 days after the onset of symptoms. Sixty percent responded to corticosteroids and survived. The discrepancies between the response rates between these two studies and ours could be attributed to the lower MELD score of our patients, the earlier initiation of treatment, the higher doses of corticosteroids used, and the route of administration.
The long-term response of patients who were treated >12 months was significantly better in original AS-AIH patients. This could be attributed to the shorter disease duration and the milder fibrosis in histology. Of interest, the presence of original AS-AIH was the only independent predictor for achieving CR after prompt initiation of high-dose i.v. corticosteroids, and the withdrawal of corticosteroids was also significantly more frequent in original AS-AIH than not-AS-AIH patients. However, the type of treatment did not seem to affect response to treatment.
Our study has some limitations: (i) the effect on response to treatment with i.v. corticosteroids in original AS-AIH vs. oral corticosteroids in not-AS-AIH patients cannot be excluded; (ii) although the kind of treatment schedule seems not to affect the treatment response, there was a lack of homogeneity in treatment schedules because a case-by-case clinical decision was made in an attempt to ensure pulsed steroids were used only by original AS-AIH patients with fewer comorbidities; and (iii) it was a retrospective, single-center, real-world study. However, the use of our criteria shows that if intense immunosuppression (either i.v. pulsed steroids or i.v. high prednisolone dose at 1.5 mg/kg/day) starts promptly enough, deterioration of liver function and ALF development can be prevented.
In conclusion, our study suggests that in early stages of original AS-AIH, high-dose i.v. corticosteroids could be life-saving; therefore, this treatment should be started as soon as possible (the sooner the better) before full-blown ALF develops. This prompt initiation appears to prevent disease deterioration, but it does not seem to increase mortality (long-term overall survival, 97%; median follow-up, 5.4 years). Indeed, in our hands, this kind of treatment in original AS-AIH patients seems to achieve, in the long term, higher probability of CR on maintenance therapy and higher corticosteroids withdrawal rates compared to not-AS-AIH cases. Our findings need of course validation from other groups in the field in order to definitely address the urgent unmet need of AS-AIH management. However, randomized control studies using high-dose corticosteroids vs. conventional treatment schedules in this urgent situation in AIH could be unethical.
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